Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats

Life Sciences

Volumn 83, Issue 9-10, 2008, Pages 313-317

  Lin, Jeng Feng ^a   Lin, Su Man ^b   Chih, Chun Lien ^c   Nien, Mao Wei ^c   Su, Hsin Hui ^d   Hu, Bo Ruei ^d   Huang, Shiang Suo ^d   Tsai, Shen Kou ^c  

^a TAIPEI TZU CHI HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^d Pediatric Dentistry   (Taiwan)

Author keywords

Atrial natriuretic peptide; Cardioprotection; Ischemia; Myocardial infarction; Resveratrol; Transforming growth factor

Indexed keywords

ATRIAL NATRIURETIC FACTOR; MESSENGER RNA; POLYPHENOL DERIVATIVE; RESVERATROL; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ECHOCARDIOGRAPHY; GRAPE; HEART DILATATION; HEART INFARCTION SIZE; HEART LEFT VENTRICULAR DILATATION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEMODYNAMICS; HISTOLOGY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RED WINE; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE I; ECHOCARDIOGRAPHY; HEMODYNAMICS; MALE; MICE; MYOCARDIAL ISCHEMIA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR REMODELING;

RATTUS; VITACEAE;

EID: 49549114451     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.06.016     Document Type: Article

References (23)

1. Ago T., and Sadoshima J. GDF15, a cardioprotective TGF-β superfamily protein. Circulation Research 98 (2006) 294-297
2. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., and Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 (2006) 337-342
3. Baur J.A., and Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nature Reviews. Drug Discovery 5 (2006) 493-506
4. Böhm M., Rosenkranz S., and Laufs U. Alcohol and red wine: impact on cardiovascular risk. Nephrology Dialysis Transplantation 19 (2004) 11-16
5. Bookout A., and Mangelsdorf D.J. Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nuclear Receptor Signaling 1 (2003) 1-7
6. Cruz M.N., Luksha L., Logman H., Poston L., Agewall S., and Kublickiene K. Acute responses to phytoestrogens in small arteries from men with coronary heart disease. American Journal of Physiology. Heart and Circulatory Physiology 290 (2006) H1969-H1975
7. Frankel E.N., Waterhouse A.L., and Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet 341 (1993) 1103-1104
8. Giovannini L., Migliori M., Longoni B.M., Giovannini L., Migliori M., Longoni B.M., Das D.K., Bertelli A.A., Panichi V., Filippi C., and Bertelli A. Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys. American Journal of Physiology. Heart and Circulatory Physiology 37 (2001) 262-270
9. Huang S.S., Tsai M.C., Chih C.L., Hung L.M., and Tsai S.K. Resveratrol reduction of infarct size in long-evans rats subjected to focal cerebral ischemia. Life Science 69 (2001) 1057-1065
10. Hung L.M., Su M.J., and Chen J.K. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radical Biology & Medicine 36 (2004) 774-781
11. Kiziltepe U., Turan N.N.D., Han U., Ulus A.T., and Akar F. Resveratrol, a red wine polyphenol, protects spinal cord from ischemia-reperfusion injury. Journal of Vascular Surgery 40 (2004) 138-145
12. Kuwahara F., Kai H., Tokuda K., Kai M., Takeshita A., Egashira K., and Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106 (2002) 130-135
13. Mizutani K., Ikeda K., Kawai Y., and Yamori Y. Protective effect of resveratrol on oxidative damage in male and female stroke-prone spontaneously hypertensive rats. Clinical and Experimental Pharmacology and Physiology 28 (2001) 55-59
14. Olas B., and Wachowicz B. Resveratrol, a phenolic antioxidant with effects on blood platelet functions. Platelets 16 (2005) 251-260
15. Omland T., Aarsland T., Aakvaag A., Lie R.T., and Dickstein K. Prognostic value of plasma atrial natriuretic factor, norepinephrine, and epinephrine in acute myocardial infarction. American Journal of Cardiology 72 (1993) 255-259
16. Orallo F., Alvarez E., Camina M., Leiro J.M., Gomez E., and Fernandez P. The possible implication of transresveratrol in the cardioprotective effects of long-term moderate wine consumption. Molecular Pharmacology 61 (2002) 294-302
17. Pelzer T., Loza P.A.A., Hu K., Bayer B., Dienesch C., Calvillo L., Couse J.F., Korach K.S., Neyses L., and Ertl G. Increased mortality and aggravation of heart failure in estrogen receptor-β knockout mice after myocardial infarction. Circulation 111 (2005) 1492-1498
18. Pfeffer M.A., Pfeffer J.M., Fishbein M.C., Fletcher P.J., Spadoro J., Kloner R.A., and Braunwald E. Myocardial infarct size and ventricular function in rats. Circulation Research 44 (1979) 503-512
19. Renaud S., and de Lorgeril M. Wine, alcohol, platelets and the French paradox for coronary heart disease. Lancet 339 (1992) 1523-1526
20. Shigematsu S., Ishida S., Hara M., Takahashi N., Yoshimatsu H., Sakata T., and Korthuis R.J. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free radical biology & Medicine 34 (2003) 810-817
21. Stein B.C., and Levin R.I. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. American Heart Journal 135 (1998) 914-923
22. Szewczuk L.M., Forti L., Stivala L.A., and Penning T.M. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. Journal of biological chemistry 279 (2004) 22727-22737
23. Wallerath T., Deckert G., Ternes T., Anderson H., Li H., Witte K., and Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhance expression and activity of endothelial nitric oxide synthase. Circulation 106 (2002) 1652-1658